NBIX vs OLED · P/E 45, rev $2.36B vs P/E 33, rev $647.7M
Neurocrine Biosciences Inc (NBIX) versus Universal Display (OLED) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Universal Display (OLED) is a electronic components company listed on US.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported OLED revenue for 2024-12-31 was $647.7M. Net income was $222.1M. Revenue was up 12.4% from 2023-12-31 to 2024-12-31. OLED currently screens at market cap $7.49B and trailing P/E 32.8.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. OLED currently screens at market cap $7.49B and trailing P/E 32.8.
Not investment advice. Open the NBIX and OLED stock pages for the full models.
Not investment advice.